ImmunoCellular Therapeutics, Ltd.
IMUC
IMUC was delisted on the 16th of October, 2018.
18 hedge funds and large institutions have $348K invested in ImmunoCellular Therapeutics, Ltd. in 2017 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 3 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
57% more capital invested
Capital invested by funds: $221K → $348K (+$127K)
13% more funds holding
Funds holding: 16 → 18 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$267K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$21.4K |
| 3 |
VF
Virtu Financial
New York
|
+$15.3K |
| 4 |
Bank of New York Mellon
New York
|
+$12.2K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
+$11.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$300 |
IMUC Hedge Fund Activity: Q3 2017 in Review
18 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in ImmunoCellular Therapeutics, Ltd. (IMUC) for Q3 2017, worth a combined $348K — up 57% from $221K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new IMUC positions and 3 closed out — a net gain of 3 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $267K. The largest seller was Vanguard Group, cutting an estimated $300.
- 18 institutional investors held ImmunoCellular Therapeutics, Ltd. (IMUC) as of Q3 2017, up from 16 in Q2 2017.
- Funds reported $348K of ImmunoCellular Therapeutics, Ltd. stock for Q3 2017, up 57% quarter-over-quarter.
- 6 funds opened new ImmunoCellular Therapeutics, Ltd. positions in Q3 2017 and 3 closed out, a net change of +3 holders.
- The largest ImmunoCellular Therapeutics, Ltd. buyer in Q3 2017 was Renaissance Technologies, an estimated $267K added.
- The largest ImmunoCellular Therapeutics, Ltd. seller in Q3 2017 was Vanguard Group, an estimated $300 sold.
Based on aggregated 13F filings for Q3 2017.